February 2014

Charles River Laboratories is first CRO to join Exostar Life Science Identity Hub

Friday, February 28, 2014

Charles River Laboratories is the first CRO to join Exostar’s rapidly growing life sciences community, which currently includes numerous CROs among the more than 500 organizations and 10,000 individuals in almost 50 countries worldwide.  The Exostar Life Sciences Identity Hub brings CROs, pharmaceutical manufacturers and academic institutions together to facilitate secure collaboration, reduce capital and operating expenditures and drive revenue by enhancing productivity and speeding time-to-market.

[Read More]

RedHill Biopharma, Salix Pharmaceuticals ink license agreement

Friday, February 28, 2014

Salix Pharmaceuticals, a North Carolina-based developer and marketer of prescription pharmaceutical products and medical devices, and RedHill Biopharma, an emerging Israeli biopharmaceutical company, have entered into an exclusive agreement by which Salix has licensed the worldwide exclusive rights to RedHill’s RHB-106 encapsulated formulation for bowel preparation and rights to other purgative developments.

[Read More]

BBK Worldwide launches Bio Notifier Plus

Friday, February 28, 2014

BBK Worldwide, a provider of patient recruitment, has launched BIO Notifier Plus, which utilizes a global opt-in physician database, a proprietary rating and ranking system and in-country direct physician contact to bring specialists to clinical trials.

[Read More]

Parkinson’s Biomarker initiative expands study of genetics

Friday, February 28, 2014

The Parkinson’s Progression Markers Initiative (PPMI), a large-scale biomarker study sponsored by The Michael J. Fox Foundation for Parkinson’s Research (MJFF), is expanding to study individuals with genetic mutations associated with Parkinson’s disease (PD). Researchers hope that greater understanding of the biology and clinical features of these participants—people with or at risk to develop Parkinson’s—will lead to therapeutics that would help all Parkinson’s patients and ultimately provide strategies to prevent disease onset.

[Read More]

CluePoints expands global team

Friday, February 28, 2014

CluePoints, a provider of Risk-Based Monitoring (RBM) solutions for clinical trials, has announced three new appointments to its global team. John Colby and Elizabeth Polvent join the company’s U.S business development team, fulfilling a key element in its strategy for growth, while CluePoints also welcomes Jean Stéphenne, president of the board of directors of GlaxoSmithKline Biologicals, as a member of its board.

[Read More]

Sinovac’s EV71 vaccine produces positive phase III clinical trial results

Friday, February 28, 2014

Sinovac Biotech, a provider of biopharmaceutical products in China, has announced that Phase III clinical trial results for its proprietary Enterovirus 71 (EV71) vaccine have been published online in the February 27 issue of TheNew England Journal of Medicine (NEJM). The clinical results showed the efficacy of the vaccine against EV71-associated hand, foot and mouth disease (HFMD), or herpangina, was 94.8% among infants and young children and an anti-EV71 neutralizing antibody titer of 1:16 was associated with protection against EV71 associated HFMD or herpangina. As outlined in the NEJM article, Sinovac’s vaccine also demonstrated a 100% efficacy rate against EV71-associated hospitalization and against HFMD with neurologic complications, the main cause of fatalities.

[Read More]